Open AccessDrug resistance and optimizing dolutegravir regimens for adolescents and young adults failing antiretroviral therapy
Author(s) -
Vinie Kouamou,
Justen Manasa,
David Katzenstein,
A M McGregor,
Chiratidzo E. Ndhlovu,
Tariro Makadzange
Publication year - 2019
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000002284
Subject(s) - dolutegravir , regimen , interquartile range , medicine , protease inhibitor (pharmacology) , reverse transcriptase inhibitor , drug resistance , lopinavir , lamivudine , viral load , virology , pharmacology , antiretroviral therapy , human immunodeficiency virus (hiv) , virus , biology , genetics , hepatitis b virus
The integrase strand inhibitor dolutegravir (DTG) combined with tenofovir and lamivudine (TLD) is a single tablet regimen recommended for 1st, 2nd and 3rd-line public health antiretroviral therapy (ART). We determined drug resistance mutations (DRMs) and evaluated the predictive efficacy of a TLD containing regimen for viremic adolescents and young adults in Harare, Zimbabwe.